JP2020534269A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534269A5 JP2020534269A5 JP2020514936A JP2020514936A JP2020534269A5 JP 2020534269 A5 JP2020534269 A5 JP 2020534269A5 JP 2020514936 A JP2020514936 A JP 2020514936A JP 2020514936 A JP2020514936 A JP 2020514936A JP 2020534269 A5 JP2020534269 A5 JP 2020534269A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable domain
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024060206A JP2024099539A (ja) | 2017-09-14 | 2024-04-03 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子－１（ｃｌｌ－１）に結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558510P | 2017-09-14 | 2017-09-14 | |
| US62/558,510 | 2017-09-14 | ||
| PCT/US2018/050916 WO2019055677A1 (en) | 2017-09-14 | 2018-09-13 | NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060206A Division JP2024099539A (ja) | 2017-09-14 | 2024-04-03 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子－１（ｃｌｌ－１）に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020534269A JP2020534269A (ja) | 2020-11-26 |
| JP2020534269A5 true JP2020534269A5 (enExample) | 2021-10-21 |
Family
ID=65723086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514936A Pending JP2020534269A (ja) | 2017-09-14 | 2018-09-13 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子−１（ｃｌｌ−１）に結合するタンパク質 |
| JP2024060206A Pending JP2024099539A (ja) | 2017-09-14 | 2024-04-03 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子－１（ｃｌｌ－１）に結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060206A Pending JP2024099539A (ja) | 2017-09-14 | 2024-04-03 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子－１（ｃｌｌ－１）に結合するタンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200277384A1 (enExample) |
| EP (1) | EP3681532A4 (enExample) |
| JP (2) | JP2020534269A (enExample) |
| KR (1) | KR20200051789A (enExample) |
| CN (1) | CN111432832A (enExample) |
| AU (1) | AU2018331412A1 (enExample) |
| BR (1) | BR112020005078A2 (enExample) |
| CA (1) | CA3075857A1 (enExample) |
| EA (1) | EA202090718A1 (enExample) |
| IL (1) | IL273206A (enExample) |
| MA (1) | MA50255A (enExample) |
| MX (1) | MX2020002880A (enExample) |
| SG (1) | SG11202002298PA (enExample) |
| WO (1) | WO2019055677A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| EP3765516A2 (en) * | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN112912400B (zh) | 2018-10-19 | 2025-05-30 | 明尼苏达大学董事会 | Nk接合子分子及其使用方法 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| KR20220004751A (ko) | 2019-05-04 | 2022-01-11 | 인히브릭스, 인크. | CLEC12a 결합 폴리펩타이드 및 이의 용도 |
| AR119393A1 (es) * | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| BR112022007128A2 (pt) * | 2019-10-15 | 2022-07-05 | Dragonfly Therapeutics Inc | Ligação de proteínas nkg2d, cd16 e flt3 |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2021226163A2 (en) * | 2020-05-06 | 2021-11-11 | Dragonfly Therapeutics, Inc. | Antibodies targeting clec12a and use thereof |
| AU2021268340A1 (en) * | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| PE20241789A1 (es) | 2021-04-26 | 2024-09-06 | Millennium Pharm Inc | Anticuerpos anti-clec12a y usos de los mismos |
| CN113817065B (zh) * | 2021-09-06 | 2023-04-18 | 深圳市乐土生物医药有限公司 | 一种抗her2的多肽及其用途 |
| CN115850476B (zh) * | 2022-08-09 | 2023-09-05 | 合源康华医药科技(北京)有限公司 | 一种cll1抗体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040115198A1 (en) * | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
| WO2007002905A1 (en) * | 2005-06-29 | 2007-01-04 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| WO2009077483A1 (en) * | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| ES2550384T3 (es) * | 2008-12-18 | 2015-11-06 | Dana-Farber Cancer Institute, Inc. | NKG2D-Fc para la inmunoterapia |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| BR112015006824A2 (pt) * | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| EP3851457A1 (en) * | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
| MX2019010156A (es) * | 2017-02-27 | 2020-01-09 | Dragonfly Therapeutics Inc | Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2. |
-
2018
- 2018-09-13 MX MX2020002880A patent/MX2020002880A/es unknown
- 2018-09-13 BR BR112020005078-4A patent/BR112020005078A2/pt not_active Application Discontinuation
- 2018-09-13 MA MA050255A patent/MA50255A/fr unknown
- 2018-09-13 US US16/645,613 patent/US20200277384A1/en not_active Abandoned
- 2018-09-13 JP JP2020514936A patent/JP2020534269A/ja active Pending
- 2018-09-13 KR KR1020207010605A patent/KR20200051789A/ko not_active Ceased
- 2018-09-13 EA EA202090718A patent/EA202090718A1/ru unknown
- 2018-09-13 WO PCT/US2018/050916 patent/WO2019055677A1/en not_active Ceased
- 2018-09-13 SG SG11202002298PA patent/SG11202002298PA/en unknown
- 2018-09-13 CN CN201880072887.1A patent/CN111432832A/zh active Pending
- 2018-09-13 EP EP18856132.8A patent/EP3681532A4/en active Pending
- 2018-09-13 AU AU2018331412A patent/AU2018331412A1/en not_active Abandoned
- 2018-09-13 CA CA3075857A patent/CA3075857A1/en active Pending
-
2020
- 2020-03-10 IL IL273206A patent/IL273206A/en unknown
-
2024
- 2024-04-03 JP JP2024060206A patent/JP2024099539A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2025200204A1 (en) | Chimeric antigen receptors for the treatment of cancer | |
| CN110551221B (zh) | 一种双特异性抗体及其制备方法与应用 | |
| CN105051066B (zh) | 作为T细胞衔接器的双特异性IgG抗体 | |
| JP2025060941A5 (enExample) | ||
| Castillo et al. | Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders | |
| TWI867066B (zh) | 靶向flt3之抗體及其用途 | |
| CA3020864A1 (en) | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| Felten et al. | Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases | |
| US11384146B2 (en) | BTLA-binding antibodies for modulating immune response and treating disease | |
| CN107406506A (zh) | 用于治疗急性髓系白血病的抗cd38抗体 | |
| TW201231066A (en) | Pan-HER antibody composition | |
| JP2018520101A5 (enExample) | ||
| Sacchi et al. | Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab | |
| US9624310B2 (en) | Methods of using bi-specific antibodies for treating B-cell-mediated autoimmune diseases or auto-reactive B-cells | |
| JP2024521408A (ja) | Ｃｄ２０、ｎｋｐ４６、ｃｄ１６に結合し、かつｉｌ－２にコンジュゲートされた多特異性抗体 | |
| CN117858906A (zh) | 与cldn18.2和cd3结合的双特异性结合剂 | |
| JP2024529494A (ja) | 抗原ターゲティング、抗ｃｄ１６ａおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用 | |
| JP2020507577A5 (enExample) | ||
| CN115697402A (zh) | 靶向clec12a的抗体及其用途 | |
| JP2023547506A5 (enExample) | ||
| JP2025175307A (ja) | 逐次抗ｃｄ１９治療 | |
| JP2021105044A (ja) | ヒトのがんを治療するための特異的抗ｃｄ３８抗体 | |
| JP2021526845A (ja) | Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療 | |
| CN116143942A (zh) | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 | |
| CN110540593A (zh) | 新型的抗cd3/抗cd20双特异性抗体 |